Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M.
Daver NG, et al. Among authors: tafuri a.
Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362.
Blood. 2023.
PMID: 36265087
Free PMC article.
Clinical Trial.